It’s interesting. Less than 10% of adult patients with cancer are treated on clinical trials, but yet the output of these studies are applied to the 90%+ of patients who were not enrolled on them. In fact, the inclusion/exclusion criteria for patients on these studies often do not resemble the clinical conditions of patients seen in routine practice. Data generated outside of clinical studies are the data that can be used to generate Real-World Evidence (RWE). I recently shared my thoughts on Medscape on the importance of “RWE.” It is here to stay, and it won’t ever replace randomized controlled studies (RCTs), but in my view, it is very complimentary to RCTs and cannot be ignored.
You can see the commentary and add your thoughts here.